Bacil Pharma Q2 results, quarter to Sep 2026
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Bacil Pharma Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994
Last close ₹18.40down ₹0.96 (4.96%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹19.36.
29 Oct: open ₹19.75, high ₹20.27, low ₹18.40
52-week range of traded prices to 29 Oct 2026
₹10.65Low, 26 Aug 2026₹61.80High, 10 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹26 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 29,650
Bacil Pharma filed its Q2 results for the quarter to Sep 2026 on 14 Oct 2026 at 7:14 pm, standalone: the listed company alone, without its subsidiaries.
Q2 results, quarter to Sep 2026
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period. Revenue from operations in the glossary
- ₹0.00 Cr
- Operating profitOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. Operating profit before depreciation (EBITDA) in the glossary
- −₹0.06 Cr
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax. Net profit in the glossary
- ₹0.15 Cr
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. Earnings per share in the glossary
- ₹0.11
From revenue to net profit, ₹ crore
- Revenue0.0
- Employee costs0.0
- Other expenses−0.1
- Operating profit−0.1
- Depreciation0.0
- Other income+0.1
- Finance costs0.0
- Profit before tax0.0
- Tax0.0
- Discontinued businesses+0.2
- Net profit0.2
Bacil Pharma results by quarter
Standalone: the listed company alone, without its subsidiaries. Latest quarter to Sep 2026. Results for the quarter to Dec 2026 are due by 14 Feb 2027, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date
Revenue and net profit by quarter, ₹ crore
- Revenue
- Net profit
- Loss
Back to profit in the quarter to Sep 2026, ₹0.15 CrA loss in 5 of the 12 quarters shown
Operating and net margin by quarter, per cent
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. Operating margin in the glossary
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
| ₹ crore | Dec 2021Q3 | Mar 2022 | Jun 2022Q1 | Sep 2022 | Dec 2022Q3 | Mar 2023Filed 16 May | Jun 2023Q1Filed 14 Aug | Sep 2023 | Dec 2023Q3 | Mar 2024 | Jun 2024Q1 | Sep 2024 | Dec 2024Q3 | Mar 2025Q4 | Jun 2025Q1Filed 12 Aug | Sep 2025Q2 | Dec 2025Q3 | Mar 2026Q4Filed 22 May | Jun 2026Q1Filed 12 Aug | Sep 2026Q2Filed 14 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. Operating expenses in the glossary | 0.04 | 3.74 | 0.04 | 0.04 | 0.05 | 0.08 | 0.03 | 0.04 | 0.06 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 | 0.04 | 0.03 | 0.07 | 0.02 | 0.06 |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. Cost of materials and goods in the glossary | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. Employee costs in the glossary | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.01 | 0.02 | 0.03 | 0.04 | 0.02 | 0.04 | 0.04 | 0.04 | 0.03 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. Other expenses in the glossary | 0.02 | 3.72 | 0.02 | 0.02 | 0.02 | 0.06 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.03 | 0.04 | 0.08 | 0.03 | 0.02 | 0.07 | 0.02 | 0.05 |
| Operating profit before depreciation | −0.04 | −3.74 | −0.04 | −0.04 | −0.05 | −0.08 | −0.03 | −0.04 | −0.06 | −0.06 | −0.04 | −0.07 | −0.06 | −0.07 | −0.11 | −0.04 | −0.03 | −0.07 | −0.02 | −0.06 |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. Depreciation and amortisation in the glossary | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. Other income in the glossary | 0.02 | 0.01 | 0.07 | 0.04 | 0.00 | 0.01 | 0.05 | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0.00 | 0.09 | 1.00 | 0.05 | 0.06 | 0.11 | 0.09 | 0.09 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. Finance costs in the glossary | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| One-off itemsExceptional items. Gains or losses the company reports separately because they are not expected to recur, such as selling a business or writing down an asset. Exceptional items in the glossary | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | −0.02 | −3.74 | 0.02 | 0.00 | −0.04 | −0.08 | 0.02 | −0.01 | −0.02 | −0.04 | −0.03 | 0.49 | −0.06 | 0.02 | 0.89 | 0.02 | 0.04 | 0.04 | 0.07 | 0.03 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | 0.00 | −0.58 | 0.09 | 0.04 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. Effective tax rate in the glossary | – | – | 0.0% | – | – | – | 0.0% | – | – | – | – | 0.7% | – | 0.0% | 25.2% | 25.0% | 0.0% | −1,497.9% | 128.8% | 130.2% |
| Profit from discontinued businessesProfit from discontinued businesses. The profit after tax of businesses the company has sold, demerged or closed, or is about to. It is part of net profit; revenue and the lines above leave those businesses out. Profit from discontinued businesses in the glossary | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.16 |
| Net profit | −0.02 | −3.74 | 0.02 | 0.00 | −0.04 | −0.08 | 0.02 | −0.01 | −0.02 | −0.04 | −0.03 | 0.48 | −0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | −0.02 | 0.15 |
| Other comprehensive incomeOther comprehensive income. Gains and losses booked straight to net worth rather than through profit, such as changes in the value of some investments, pension plans and currency translation. Other comprehensive income in the glossary | 0.07 | 3.52 | −0.08 | 0.08 | 0.12 | −0.16 | 0.18 | −0.05 | 0.02 | 0.01 | 0.25 | −0.22 | 0.01 | −0.04 | 0.06 | 0.00 | 0.02 | −2.26 | 0.00 | 0.00 |
| Total comprehensive incomeTotal comprehensive income. Net profit plus other comprehensive income. Total comprehensive income in the glossary | 0.05 | −0.21 | −0.05 | 0.08 | 0.08 | −0.23 | 0.20 | −0.06 | 0.00 | −0.03 | 0.21 | 0.26 | −0.05 | −0.03 | 0.73 | 0.01 | 0.06 | −1.64 | −0.02 | 0.15 |
| Earnings per share | −₹0.04 | −₹6.34 | ₹0.04 | −₹0.01 | – | −₹0.13 | ₹0.03 | −₹0.02 | −₹0.04 | −₹0.07 | – | ₹0.82 | −₹0.10 | ₹0.20 | ₹0.48 | ₹0.01 | ₹0.03 | ₹0.44 | – | ₹0.11 |
Earnings per share in rupees, restated for later splits and bonuses.
The quarters either side of a change of basis do not compare. From the quarter to Sep 2026, the company reports a discontinued business.